相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
T. Nakamura et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
P. D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Yasuo Suzuki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture
Jay S. Magaziner et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis
M. Tadrous et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Goal-directed treatment of osteoporosis in Europe
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Diagnostic criteria for primary osteoporosis: year 2012 revision
Satoshi Soen et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
Hua Bai et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate
Philip N. Sambrook et al.
BONE (2012)
Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells
Maurizio Rossini et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
Richard M. Jacques et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Antiresorptive therapies for osteoporosis: a clinical overview
Jian Sheng Chen et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg
J. D. Wark et al.
OSTEOPOROSIS INTERNATIONAL (2012)
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
S. Lekamwasam et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT
Philip N. Sambrook et al.
BONE (2011)
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
Jawl-Shan Hwang et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Once-Yearly Zoledronic Acid and Days of Disability, Bed Rest, and Back Pain: Randomized, Controlled HORIZON Pivotal Fracture Trial
Jane A. Cauley et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Steven Boonen et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2011)
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial
J. D. Adachi et al.
OSTEOPOROSIS INTERNATIONAL (2011)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Efficacy and Safety of a Once-Yearly i.v. Infusion of Zoledronic Acid 5 mg Versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study
Eric S. Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid Data from the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly clinical trials program
John T. Grbic et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2010)
Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP
Anke J. Roelofs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture
Erik Fink Eriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
Pierre D. Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Michael McClung et al.
OBSTETRICS AND GYNECOLOGY (2009)
Zoledronic Acid A Review of its Use in the Treatment of Osteoporosis
Emma D. Deeks et al.
DRUGS & AGING (2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Steven Boonen et al.
KIDNEY INTERNATIONAL (2008)
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
G. H. Nancollas et al.
BONE (2006)
Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs
Jean-Michel Rondeau et al.
CHEMMEDCHEM (2006)
Zoledronic acid: A new parenteral bisphosphonate
EC Li et al.
CLINICAL THERAPEUTICS (2003)
Diagnostic criteria for primary osteoporosis: year 2000 revision
H Orimo et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2001)
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
FP Coxon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
